Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate

Core Insights - Precision BioSciences, Inc. has revealed initial results from the first administration of PBGENE-HBV in cohort 1 of the ELIMINATE-B trial, which targets chronic Hepatitis B patients who are HBeAg-negative [1][4] - The trial is designed to assess PBGENE-HBV at multiple ascending dose levels, with the first dose being 0.2 mg/kg, and aims to establish the optimal dose and administration schedule [2][4] Group 1 - PBGENE-HBV was found to be safe and well tolerated in all three participants of cohort 1 after the initial administration [2][3] - No participants experienced Grade ≥2 treatment-related adverse events or serious adverse events [3] - A significant reduction in Hepatitis B surface antigen (HBsAg) was observed in two of the three participants following the first administration [3] Group 2 - The ELIMINATE-B study is currently enrolling patients in Moldova, Hong Kong, and New Zealand [4] - The company plans to complete subsequent administrations in cohort 1 patients and will escalate to higher dose levels to effectively eliminate covalently closed circular DNA (cccDNA) and inactivate integrated HBV DNA [4] - Precision BioSciences intends to share detailed clinical data throughout 2025 [5] Group 3 - HC Wainwright analyst Patrick Trucchio maintains a Buy rating on Precision BioSciences with a price target of $60 [5] - Following the news, DTIL stock increased by 9.22$5.63 [5]